

Freedom of Information (Scotland) Act 2002

Date received	26/08/2022	Subject	Drug Treatment		
Passed to	Pharmacy	Date passed	26/08/2022	Respond by	16/09/2022
Category	Research	FOI number	2022-352		

Question/s to be answered

1. In the past 3 months (or the latest 3 months data you have available), how many metastatic non-small cell lung cancer (NSCLC) patients were treated with any of the following:

- Afatinib
- Alectinib
- Atezolizumab monotherapy
- Atezolizumab in combination
- Bevacizumab
- Brigatinib
- Capmatenib
- Ceritinib
- Crizotinib
- Dacomitinib
- Dabrafenib with Trametinib
- Docetaxel monotherapy
- Durvalumab
- Erlotinib
- Gefitinib
- Gemcitabine
- Nintedanib with Docetaxel
- Nivolumab

Freedom of Information (Scotland) Act 2002

- Osimertinib
- Paclitaxel
- Pembrolizumab monotherapy
- Pembrolizumab in combination
- Pemetrexed with Carboplatin/Cisplatin
- Tepotinib
- Vinorelbine with Cisplatin/Carboplatin
- Any other SACT
- Palliative care only

In accordance with FOISA s 17(1), NHS Shetland confirms that it does not hold the information requested.

Shetland patients are treated by NHS Grampian.